Cingulate Inc. (NASDAQ:CING) Shares Acquired by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC increased its stake in shares of Cingulate Inc. (NASDAQ:CING) by 281.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 43,022 shares of the company’s stock after purchasing an additional 31,746 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Cingulate were worth $212,000 as of its most recent SEC filing.

Separately, AlphaMark Advisors LLC raised its position in Cingulate by 50,000.0% during the 4th quarter. AlphaMark Advisors LLC now owns 5,010 shares of the company’s stock worth $25,000 after buying an additional 5,000 shares during the last quarter. 41.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CING. Roth Capital upgraded shares of Cingulate to a “strong-buy” rating in a research note on Friday, January 10th. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Cingulate in a research note on Thursday, March 6th. Finally, Roth Mkm began coverage on Cingulate in a research note on Friday, January 10th. They issued a “buy” rating and a $12.00 price target on the stock.

Cingulate Trading Up 1.9 %

Shares of CING opened at $3.68 on Thursday. Cingulate Inc. has a twelve month low of $1.80 and a twelve month high of $20.83. The firm has a market capitalization of $13.87 million, a P/E ratio of -0.25 and a beta of -0.87. The firm’s 50-day moving average is $4.09 and its two-hundred day moving average is $4.37.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.